Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "New Discoveries in Drug Targets and Delivery for Alzheimer’s Disease"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 30 June 2023 | Viewed by 2976
Special Issue Editors
Interests: CNS drug delivery; blood–brain barrier; CNS pharmacokinetics; intra-brain delivery; membrane transporters
Special Issues, Collections and Topics in MDPI journals
Interests: CNS drug delivery; blood–brain barrier; glia–neuron interactions; brain physiopathology
Special Issue Information
Alzheimer’s Disease (AD), the most common cause of dementia, affects over 40 million people worldwide. The situation is expected to intensify in the coming years, with devastating social and economic effects. Despite intensive clinical research efforts, there are currently no treatments or effective preventive strategies for AD. In fact, FDA-approved drugs only relieve symptoms. The main reasons for AD treatment’s failure are the multifactorial and heterogeneous physiopathological mechanisms of the disease, erroneous selection of drug targets, lack of relevant animal models, and obstacles in drug delivery into the brain due to the high selectivity of the blood–brain barrier, which limits the access of therapeutic agents into the central nervous system.
Therefore, this Special Issue aims to collect original research articles and reviews with the most relevant and innovative findings in the field of AD. Manuscripts dealing with new targets and therapeutic strategies, pharmaceutical formulations, and drug delivery systems as well as relevant models used for the development of effective AD treatments are of great interest.
We look forward to receiving your contributions.
Dr. Elena Puris
Dr. Sabrina Petralla
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s disease
- therapeutic strategies
- drug delivery
- drug targets
- blood–brain barrier
- animal models